(Q37883015)

24 August 2017

1 reference

title

Statins, inflammation and kidney disease (English)

1 reference

24 August 2017

0 references

Vera Krane

1

1 reference

24 August 2017

Christoph Wanner

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

31 May 2011

1 reference

Nature Reviews Nephrology

24 August 2017

published in

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

385-397

1 reference

Atherosclerosis — An Inflammatory Disease

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

CRP polymorphisms and progression of chronic kidney disease in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

The 2007 ERA-EDTA Registry Annual Report-a Précis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Statin use and sepsis events [corrected] in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Cystatin-C and inflammatory markers in the ambulatory elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Biomarkers of inflammation and progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation, malnutrition and atherosclerosis in end-stage renal disease: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation and atherosclerosis in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

The pathophysiologic roles of interleukin-6 in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-Reactive Protein, Interleukin-6, and Soluble Adhesion Molecules as Predictors of Progressive Peripheral Atherosclerosis in the General Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Genetically elevated C-reactive protein and ischemic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein as an outcome predictor for maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

White blood cells as a novel mortality predictor in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Associations between circulating inflammatory markers and residual renal function in CRF patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Cardiovascular disease risk status in elderly persons with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein is associated with renal function abnormalities in a non-diabetic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein and body mass index independently predict mortality in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of pravastatin in people with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Statins for improving renal outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation and resistance to treatment with recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Managing erythropoietin hyporesponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Hyporesponsiveness to erythropoietic therapy due to chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Cellular mechanism of resistance to erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Statins for the prevention and treatment of infections: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Statins inhibit HIV-1 infection by down-regulating Rho activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Telomerase activity is decreased in peripheral blood mononuclear cells of hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Telomere shortening and haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Cellular senescence, cardiovascular risk, and CKD: a review of established and hypothetical interconnections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Safety and efficacy of atorvastatin in patients with severe renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

The effects of lipid-lowering agents on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation, serum C-reactive protein, and erythropoietin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

12 December 2020

C-reactive protein and cardiovascular disease in peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Coronary C-reactive protein distribution: its relation to development of atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Activation of the acute phase response and complement C3 in patients with IgA nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Inflammation and endothelial activation are linked to renal function in long-term kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Is inflammation prior to renal transplantation predictive for cardiovascular and renal outcomes?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

HMG CoA reductase inhibitors (statins) for dialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Decreased erythropoietin response in patients with the anemia of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Statins as a newly recognized type of immunomodulator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.62

K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients

31 March 2020

1 reference

12 December 2020

1 reference

12 December 2020

Clinical epidemiology of cardiovascular disease in chronic renal disease

1 reference

12 December 2020

Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients

1 reference

12 December 2020

1 reference

12 December 2020

Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.

1 reference

12 December 2020

Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients?

1 reference

12 December 2020

K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease

1 reference

12 December 2020

Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen

1 reference

12 December 2020

Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2011.62

1 reference

24 August 2017

1 reference